MannKind expands United Therapeutics partnership for second inhaled therapy

MannKind Corporation (NASDAQ: MNKD) announced that United Therapeutics Corporation (NASDAQ: UTHR) has exercised its option to develop a second dry powder inhalation therapy under their 2018 collaboration agreement.

The original agreement led to U.S. FDA approval of Tyvaso DPI in May 2022, the first dry powder inhalation treatment for pulmonary hypertension. The expanded agreement allows United Therapeutics to include additional active ingredients in the license.

Under the expanded collaboration, MannKind will formulate a second investigational molecule using its Technosphere platform, while United Therapeutics will conduct preclinical and clinical development. MannKind will receive a $5 million upfront payment and is eligible for up to $35 million in development milestones plus 10% royalties on net sales of any resulting product.

"Building on the success of Tyvaso DPI, we are proud to deepen our collaboration with United Therapeutics to bring innovative patient-centric inhaled therapies to patients living with pulmonary hypertension," said Michael Castagna, Chief Executive Officer of MannKind Corporation.

Formulation and development activities for the new investigational molecule will begin immediately, according to the company's statement.

MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases using dry-powder formulations and inhalation devices.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• Meta's Zuckerberg Says Ai Agent Tech Progressing Slower Than Expected - Reuters
• VivoPower shifts focus to AI data centers, revises unit spinoff plans